Mountain Crest Acquisition Corp. V intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. The company was incorporated in 2021 and is based in New York, New York. Mountain Crest Acquisition Corp. V operates as a subsidiary of Mountain Crest Global Holdings LLC.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
8-K - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
25-NSE - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
10-K - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
NT 10-K - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
SCHEDULE 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
8-K - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
10-Q - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
8-K - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
8-K - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
DEF 14A - Mountain Crest Acquisition Corp. V (0001859035) (Filer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
3 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
4 - Mountain Crest Acquisition Corp. V (0001859035) (Issuer)
NEW YORK, USA and SEOUL, Korea, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation formed as a special purpose acquisition company ("Mountain Crest V"), with its common stock publicly traded on The Nasdaq Stock Market under the trading symbol "MCAG" and CUBEBIO Co., Ltd., a corporation ("chusik hoesa") organized under the laws of Korea ("CUBEBIO"), which has an innovative technology that diagnoses cancer at an early stage using urine, today announced that the parties entered into a definitive business combination agreement, dated August 29, 2024 (the "BCA") for a proposed business combination transaction through which CUBEBIO plans to become a publ
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ:MCAG, the "Company"))) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on July 18, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to timely file (i) its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), as described more fully in the Company's Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission (the "SEC") on Apr
NEW YORK, USA and SEOUL, Korea, May 02, 2024 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V, a Delaware corporation ("Mountain Crest V"), that is a Nasdaq-listed (NASDAQ:MCAG) special purpose acquisition company ("SPAC"), and CUBEBIO Co., Ltd., a Korea-based company ("CUBEBIO"), which has an innovative technology that diagnoses cancer at an early stage using urine, today announced that the parties entered into a non-binding term sheet on April 26, 2024 for a proposed business combination through which CUBEBIO plans to become a public company with its securities listed on The Nasdaq Stock Market. Mountain Crest V is the fifth vehicle in the Mountain Crest family of SPACs, the manage
NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) (the "Company") announced today that it has received approval from the Nasdaq Stock Market ("Nasdaq") to transfer the listing of its securities from the Nasdaq Global Market to the Nasdaq Capital Market. The Company's common stock, units and rights will continue to trade under the symbols "MCAG," "MCAGU" and "MCAGR," respectively and trading of its common stock, units and rights will be unaffected by this transfer. This transfer will be effective as of the opening of business on October 27, 2023. As previously disclosed, the Company received notifications from Nasdaq indicating the Company failed
SINGAPORE and BETHESDA, Md., May 30, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotechnology company focused on discovering and developing precision oncology therapeutics, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating AUM001 for the treatment of metastatic colorectal cancer (MSS CRC). AUM001 is a mRNA translation inhibitor that targets MNK 1/2 and the chokepoint of multiple pro-oncogenic signalling pathways for the treatment of MSS CRC. "Dosing the first patient in AUM001's Phase 2 trial is a major milestone in advancing our mission to build an industry-leading portfolio of innovative therapies desi
SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotechnology company focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, announced today that the management team will participate in the Inaugural EF Hutton Global Conference (the "Conference") in New York, New York from May 10th to May 11th. The AUM management team will host investor meetings at the Conference. As previously announced on October 20, 2022, AUM entered into a definitive business combination agreement (the "Agreement") with Mountain Crest Acquisition
SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) for its product candidate, AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma. In November 2022, the FDA granted Orphan Drug Designation (ODD) for AUM302. "Neuroblastoma is the third most common pediatric cancer, and more than 90 percent o
SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation for AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma. "The Orphan Drug Designation for AUM302 is the second Orphan Drug Designation we have received for our products this year, marking a significant milestone for AUM as we advance our diverse pipeline of
SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced it has received Human Research Ethics Committee ("HREC") approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia. Ethics approval is confirmation that AUM has completed all the necessary pre-clinical safety and efficacy testing of AUM001 required to commence its Phase II clinical trial in Australia. "Ethics approval in Australia provides further
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical-stage pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, announced today that their management team will participate in the BioCentury-BayHelix East-West BioPharma Summit in Redwood City, California and virtually. Vishal Doshi, founder and Chief Executive Officer of AUM, is scheduled to participate on Tuesday, November 15th at 10:30 am PT on a panel entitled, "CEO Roundtable: What Will it Take to be Successful in the Next Era of Biotech?" In addition, the
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)
SC 13G/A - Mountain Crest Acquisition Corp. V (0001859035) (Subject)